B and B Expositions Inc.

Seattle Genetics to Present Brentuximab Vedotin and Dacetuzumab Data at the 51st American Society of Hematology Annual Meeting and Exposition.
Blood Weekly; 12/17/2009; 1422 words; Seattle Genetics, Inc. (Nasdaq: SGEN...2009 Meeting and Exposition being held December...therapy in diffuse large B-cell lymphoma Sunday...D., Genentech, Inc (see also Seattle...relapsed diffuse large B-cell lymphoma Monday...

Eleven Rigel Product Candidate Presentations at 2009 ASH Meeting.
Blood Weekly; 12/17/2009; 679 words; ...Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL...ASH) Meeting and Exposition in New Orleans, Louisiana...activity in distinct B-cell lymphoma models...Rigel Pharmaceuticals, Inc.). On Monday, December...warranted. Keywords: B-Cell Lymphoma, Clinical...

Study findings from Heidelberg University provide new insights into pharmacokinetics.
Biotech Week; 12/16/2009; 1168 words; ...caused a 20-fold increase in exposition of tilidine in serum [AUC...active nortilidine," wrote B. Grun and colleagues, Heidelberg...additional information, contact B. Grun, Heidelberg University...is: Blackwell Publishing Inc., 350 Main St., Malden...

REP. BART GORDON HOLDS A HEARING ON THE AEROSPACE WORKFORCE
Political Transcript Wire; 12/11/2009; 16416 words; ...PRESIDENT, STRATEGY AND TECHNOLOGY, MOOG INC. MARION BLAKEY, CURRENT PRESIDENT AND CEO...now the assistant manager at the California exposition and state fair. And as most all of us here...really the -- the good work that you have b

ImmunoGen Presents SAR3419 Phase I Study Results in non-Hodgkin's Lymphoma at ASH.
Health & Beauty Close-Up; 12/10/2009; 1156 words; ImmunoGen, Inc., a biopharmaceutical...51st Annual Meeting and Exposition. In a release, the...among patients with B-cell non-Hodgkin...s lymphoma and other B-cell malignancies...for the treatment of B-cell non-Hodgkin...